Primary al amyloid polyneuropathy successfully treated with high-dose melphalan followed by autologous stem cell transplantation

Muscle and Nerve

Volumn 41, Issue 1, 2010, Pages 138-143

  Katoh, Nagaaki ^a   Matsuda, Masayuki ^a   Yoshida, Takuhiro ^a   Yazaki, Masahide ^a   Morita, Hiroshi ^a   Sakashita, Kazuo ^a   Ikeda, Shu Ichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AL amyloidosis; Amyloid neuropathy; Autologous peripheral blood stem cell transplantation; M protein

Indexed keywords

MELPHALAN;

ACHILLES REFLEX; ADULT; AMYLOID NEUROPATHY; ANAMNESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BODY MASS; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GAIT DISORDER; HEART FUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIGHT CHAIN; MALE; MOTOR NERVE CONDUCTION; MUSCLE ACTION POTENTIAL; MUSCLE STRENGTH; MYELINATED NERVE; NERVE FUNCTION; NEUROLOGIC EXAMINATION; PERIPHERAL BLOOD STEM CELL; PERIPHERAL NERVE; PRIORITY JOURNAL; PROTEINURIA; TENDON REFLEX;

ADULT; AMYLOID NEUROPATHIES; BIOPSY; DIAGNOSIS, DIFFERENTIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROMYOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MUSCLE, SKELETAL; MYELOABLATIVE AGONISTS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 73949116286     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21483     Document Type: Article

References (22)

1. Kyle RA, Gertz MA. Primary systemic amyloidosis. Clinical and laboratory features in 474 cases. Semin Hematol 1995; 32:45-59.
2. Ikeda S, Nakazato M, Ando Y, Sobue G. Familial transthyretin-type amyloid polyneuropathy in Japan. Clinical and genetic heterogeneity. Neurology 2002;58:1001-1007.
3. Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, et al. Misdiagnosis of hereditary amyloidosis as AL amyloidosis. N Engl J Med 2002;346:1786-1791.
4. Comenzo RL, Vosburgh E, Simms RW, Bergethon P, Sarnacki D, Finn K, et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood 1996;88:2801-2806.
5. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85-93.
6. Matsuda M, Yamada T, Gono T, Shimojima Y, Ishii W, Fushimi T, et al. Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis. Intern Med 2005;44:428-433.
7. Tachibana N, Tokuda T, Yoshida K, Taketomi T, Nakazato M, Li YF, et al. Usefulness of MALDI/TOF mass spectrometry of immunoprecipitated serum variant transthyretin in the diagnosis of familial amyloid polyneuropathy. Amyloid J Prot Folding Disord 1999;6:282-288.
8. Matsuda M, Gono T, Shimojima Y, Hoshii Y, Ikeda S. Phenotypic analysis of plasma cells in bone marrow using flow cytometry in AL amyloidosis. Amyloid J Prot Folding Disord 2003;10:110-116.
9. Hoshii Y, Setoguchi M, Iwata T, Ueda J, Cui D, Kawano H, et al. Useful polyclonal antibodies against synthetic peptides corresponding to immunoglobulin light chain constant region for immunohistochemical detection of immunoglobulin light chain amyloidosis. Pathol Int 2001; 51:264-270.
10. Yazaki M, Fushimi T, Tokuda T, Kametani F, Yamamoto K, Matsuda M, et al. A patient with severe renal amyloidosis associated with an immunoglobulin gamma-heavy chain fragment. Am J Kidney Dis 2004;43:e23-28.
11. Gono T, Matsuda M, Shimojima Y, Ishii W, Koyama J, Sakashita K, et al. VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection. Amyloid J Prot Folding Disord 2004;11: 245-256.
12. Shimojima Y, Morita H, Kobayashi S, Takei Y, Ikeda S. Ten-year follow-up of peripheral nerve function in patients with familial amyloid polyneuropathy after liver transplantation. J Neurol 2008;255:1220-1225.
13. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002;99: 4276-4282.
14. Sanchorawala V, Wright DG, Quillen K, Finn KT, Dember LM, Berk JL, et al. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. Bone Marrow Transplant 2007;40:557-562.
15. Vucic S, Chong PS, Cros D. Atypical presentations of primary amyloid neuropathy. Muscle Nerve 2003;28:696-702.
16. Kuwabara S, Misawa S, Kanai K, Kikkawa Y, Nishimura M, Nakaseko C, et al. Autologous peripheral blood stem cell transplantation for POEMS syndrome. Neurology 2006;66: 105-107.
17. Tsuchiya A, Yazaki M, Kametani F, Takei Y, Ikeda S. Marked regression of abdominal fat amyloid in patients with familial amyloid polyneuropathy during long-term follow-up after liver transplantation. Liver Transplant 2008;14:563-570.
18. Tazawa K, Katoh N, Shimojima Y, Matsuda M, Ikeda S. Marked shrinkage of amyloid lymphadenopathy after an intensive chemotherapy in a patient with primary systemic AL amyloidosis. Amyloid J Prot Folding Disord 2009 Jul 18:1-3 [Epub ahead of print].
19. Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003;122:78-84.
20. Liao R, Jain M, Teller P, Connors LH, Ngoy S, Skinner M, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 2001;104:1594-1597.
21. Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, Skinner M, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004;94:1008-1010.
22. Kyle RA, Dyck PJ. Amyloidosis and neuropathy. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF, editors. Peripheral neuropathy, 3rd ed. Philadelphia: W.B. Saunders; 1993. p 1294-1309.